CD4 testing continues to be used to assess eligibility for elements of a package of care, including tracking disease progression, monitoring the effectiveness of antiretroviral treatment (ART), adapting adherence support, antimicrobial prophylaxis and preemptive treatment, screening for opportunistic infections, and vaccination management, as well as ART prioritization (2, 3). This evidence concerns the gene CD4 and Opportunistic infection.